MTH1-IN-2
Modify Date: 2024-01-04 08:08:54
MTH1-IN-2 structure
|
Common Name | MTH1-IN-2 | ||
|---|---|---|---|---|
| CAS Number | 901044-91-5 | Molecular Weight | 469.55 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H27N3O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MTH1-IN-2MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity[1]. |
| Name | MTH1-IN-2 |
|---|
| Description | MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity[1]. |
|---|---|
| Related Catalog | |
| Target |
MTH1[1] |
| In Vitro | The enzyme human MTH1 is a 2-hydroxy-dATP diphosphatase. MTH1 specifically assists RAS-induced tumors in preventing tumor- suppressive effects such as senescence whilst enabling maintenance and progression of the tumor. MTH1 inhibition helps impairing tumor growth by abrogating mitogenic signaling, epithelial-mesenchymal transition (EMT), a hallmark of progressing and aggressive tumors, anoikis inhibition and PI3K/Akt-mediated pro-survival signaling. MTH1 inhibitors induce oxidative DNA lesions[1]. |
| References |
[1]. Kilian Huber. Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer. WO2016135138A1. |
| Molecular Formula | C24H27N3O5S |
|---|---|
| Molecular Weight | 469.55 |